Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.
Saved in:
| Title: | Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study. |
|---|---|
| Authors: | Yang, Jianliang1 (AUTHOR), Song, Yongping2 (AUTHOR), Zhou, Keshu2 (AUTHOR), Li, Zhiming3 (AUTHOR), Zhang, Mingzhi4 (AUTHOR), Jing, Hongmei5 (AUTHOR), Wang, Zhen6 (AUTHOR), Yu, Li7 (AUTHOR), Meng, Wei8 (AUTHOR), Lu, Qiying8 (AUTHOR), Tian, Wenzhi8 (AUTHOR), Shi, Yuankai1 (AUTHOR) syuankai@cicams.ac.cn |
| Source: | Journal of Hematology & Oncology. 12/18/2024, Vol. 17 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
